test
test
목차
A full Shingrix course in Korea costs about 500,000 won, and the patient pays all of it. That figure rests on the 250,000-won median per dose in the 2024 disclosure by the Health Insurance Review and Assessment Service (HIRA). Free national vaccination for shingles became a topic for discussion only in October 2026. Until that debate ends, shingles vaccine cost in Korea is set clinic by clinic, and 23.9% of local governments offer no subsidy.
Contents
- How much does a shingles vaccine cost in Korea in 2026, and is it becoming free?
- What does HIRA's price data show for Shingrix, SkyZoster and Zostavax?
- Do tertiary hospitals, clinics or provinces charge more for a shingles vaccine?
- How have shingles vaccine prices and the disclosure changed since 2024?
- Why does the same shingles vaccine cost different amounts in different places?
- How can you check a shingles vaccine price and your bill in Korea?
- What do patients ask most about shingles vaccine cost in Korea?
- What should patients check now, and what should they watch next?
- What else should you read on Korea's non-covered prices?
How much does a shingles vaccine cost in Korea in 2026, and is it becoming free?
Each clinic sets the price and the patient pays it in full, and no free national shot exists in 2026. The benchmark is 250,000 won per Shingrix dose, the 2024 HIRA median reported by Dailypharm, or about 500,000 won for the two-dose course. Shingrix is the recombinant (non-live) vaccine. SkyZoster, a one-dose live vaccine, averaged 146,000 won in the same data. A Shingrix course therefore costs about 3.4 times one SkyZoster shot, a ratio calculated by the Korea Non-covered Medical Price Statistics editorial team.
Both vaccines are non-covered (bigeubyeo) services. They sit outside National Health Insurance, so each institution sets the price and the patient pays it. Covered (geubyeo) services work the other way: the government sets the fee and insurance pays most of it. What changed in autumn 2026 was the data and the debate, not the payment rule:
- September 3, 2026: HIRA published 2026 prices for 753 non-covered items (693 in 2025), collected from April 13 to June 12. Of about 74,600 institutions required to report under Article 45-2 of the Medical Service Act, 74,449 (99.8%) did (HIRA 2026 press release).
- October 1, 2026: The Vaccination Management Act passed, widening national vaccination from preventing infectious disease to preventing disease more broadly (Jaegyeong Ilbo).
- October 8, 2026: Korea Disease Control and Prevention Agency (KDCA) Commissioner Im Seung-gwan told the National Assembly audit that adding shingles to the National Immunization Program (NIP), the state-funded vaccine schedule, could now be discussed (Jaegyeong Ilbo).
- Unchanged: 175 of 230 local governments (76.1%) fund some vaccination under their own rules, and 55 (23.9%) fund none (Jaegyeong Ilbo).
No decision followed the remark. The commissioner said the target group and funding still need academic and interministerial review. KDCA plans to consider high-risk groups first and expand in phases, and it has named no age group, product or start date.
What does HIRA's price data show for Shingrix, SkyZoster and Zostavax?
Shingrix prices clustered tightly around 250,000 won in 2024, then spread out at both ends in 2025. A disclosed price is what an institution reports charging. The 2024 press reference from the Ministry of Health and Welfare (MOHW) and HIRA states that it does not reflect quality of care.
Table 1. Shingles vaccine price per dose in HIRA disclosures (won, reporting institutions nationwide)
| Year | Product (doses) | Minimum | Q1 | Median | Q3 | Maximum | Mean |
|---|---|---|---|---|---|---|---|
| 2024 | Shingrix (2), all types | 160,000 | n/r | 250,000 | n/r | 270,000 | 250,000 |
| 2024 | Shingrix (2), clinics | 250,000 | 250,000† | 250,000 | 250,000† | 250,000 | 250,000 |
| 2024 | SkyZoster (1) | n/r | n/r | n/r | n/r | n/r | 146,000 |
| 2025 | Shingrix (2) | 130,000 | n/r | n/r | n/r | 420,000‡ | n/r |
| 2025 | SkyZoster (1) | 74,700 | n/r | n/r | n/r | 300,000 | n/r |
| 2025 | Zostavax (1) | 75,000 | n/r | n/r | n/r | 400,000 | n/r |
Sources: Dailypharm on HIRA's 2024 data; Medical Observer on HIRA's 2025 data. n/r = figure not given in the cited article. † Implied, because the minimum and maximum are both 250,000 won. ‡ Published without a unit, so it can be a per-dose or a two-dose package price. HIRA's lookup holds the product-level 2026 prices from the September 3 release.
In 2024 the Shingrix maximum was only 1.08 times the median. At clinics (uiwon), where most people get the shot, every statistic was exactly 250,000 won. By 2025 the gap between the cheapest and the most expensive Shingrix price had grown from 110,000 to 290,000 won, 2.6 times wider. The minimum fell 30,000 won (18.8%) to 130,000 won. The maximum rose 150,000 won (55.6%) to 420,000 won.
That ceiling reads two ways. Taken per dose, it puts a full course at 840,000 won, 1.68 times the median course. Taken as a two-dose package, it lands 80,000 won below the median course. SkyZoster's 2025 range of 74,700 to 300,000 won runs from about half to about double its 2024 mean. The editorial team calculated every ratio and difference in this section.
Do tertiary hospitals, clinics or provinces charge more for a shingles vaccine?
No. In HIRA's 2024 data, tertiary hospitals had the lowest or near-lowest mean price for both vaccines, and the gaps between institution types were small.
Table 2. Mean price per dose by institution type, 2024 HIRA disclosure (won; difference from clinics calculated)
| Institution type | Shingrix | vs clinics | SkyZoster | vs clinics |
|---|---|---|---|---|
| Tertiary hospitals (sangeup jonghap byeongwon) | 240,000 | -10,000 (-4.0%) | 139,000 | -6,000 (-4.1%) |
| General hospitals | 250,000 | 0 | 152,000 | +7,000 (+4.8%) |
| Hospitals | 248,000 | -2,000 (-0.8%) | 151,000 | +6,000 (+4.1%) |
| Dental hospitals | n/r | n/r | 140,000 | -5,000 (-3.4%) |
| Korean medicine hospitals | 236,000 | -14,000 (-5.6%) | 147,000 | +2,000 (+1.4%) |
| Clinics | 250,000 | baseline | 145,000 | baseline |
Source: Dailypharm on HIRA's 2024 data. n/r = figure not given in the cited article.
The widest gap between institution types was 14,000 won for Shingrix (5.9% above the lowest type) and 13,000 won for SkyZoster (9.4%), both calculated from the table. A vaccine is mostly a product that every institution buys, so in 2024 hospital size did not push its price up. Imaging shows the opposite pattern, with larger hospitals often charging more.
The cheapest shots came from institutions outside this table. Long-term care hospitals, including one in Gimhae, South Gyeongsang, supplied the 2024 Shingrix minimum of 160,000 won. Buying both doses at that minimum instead of the median brings the course to 320,000 won, which is 180,000 won (36%) less.
Region: subsidies matter more than list price
Where you live changes the final bill mainly through subsidies. HIRA's lookup sets any clinic's price beside its regional median, so a province check starts from the 250,000-won national median. Subsidy rules vary far more than prices do. Jaegyeong Ilbo found local criteria that differ by age, income, residency and vaccination history. Guro-gu in Seoul limits support to basic livelihood security recipients, and many programs fund only one dose. If a program pays for one Shingrix dose only, the patient still pays 250,000 won for the second dose at the 2024 median.
How have shingles vaccine prices and the disclosure changed since 2024?
The disclosure system has changed more than the typical price. Shingrix entered the disclosure in 2024 with a range of 160,000 to 270,000 won. That same year, MSD told the Ministry of Food and Drug Safety it would stop supplying Zostavax in Korea, so later Zostavax figures increasingly reflect remaining stock. HIRA's item list grew from 693 in 2025 to 753 in 2026, 60 more items or a calculated 8.7%. The 2025 redesign of HIRA's lookup added screens comparing prices by region and institution size, plus a link to KDCA's vaccination helper site.
Two cautions follow. A single 'shingles vaccine' average now mixes a product leaving the market with two that remain, so compare products one by one. And because the 2025 figures are ranges, the documented change sits at the cheapest and most expensive ends rather than in the typical Shingrix price.
Disease burden drives the policy push. About 760,000 people were treated for shingles in 2024, Jaegyeong Ilbo reported. Roughly 73% of them were aged 50 or older, about 555,000 people by our calculation, and 28.8% of patients aged 65 and over had a recurrence. At the October audit, Rep. Kim Yun (Democratic Party) cited KDCA's 2023 priority study, which ranked shingles 4th, and called for immediate inclusion. Rep. Han Ji-a (People Power Party) wanted overall vaccination priorities set first.
Price shapes the program design too. Paying 2024 central prices, a public program would spend 146,000 won per person on SkyZoster and 500,000 won on a Shingrix course, a difference of 354,000 won. Live vaccines, however, are not safe for immunocompromised patients, and Jaegyeong Ilbo puts the recombinant vaccine's long-term efficacy above 90%. A broad program for older adults would lean toward the cheaper one-dose product. KDCA's high-risk-first approach points toward Shingrix.
Why does the same shingles vaccine cost different amounts in different places?
The same vaccine costs different amounts because no one sets a national price for it. Each institution decides its own fee for a non-covered service. HIRA only collects and publishes that fee under the reporting duty in Article 45-2 of the Medical Service Act, as the MOHW and HIRA 2024 press reference explains.
Four forces work within that freedom. Clinics anchor on a reference price: every 2024 clinic statistic for Shingrix was 250,000 won, which points to a market-wide benchmark rather than prices built from each clinic's own costs. Long-term care hospitals set the floor at 160,000 won. The patient's medical condition picks the product, because immunocompromised patients cannot safely take the cheaper live vaccine. Subsidies then reshape the final bill, so one posted price can mean full payment in one district and partial or no payment in another.
None of these forces measures quality. A lower price for the same product does not mean a weaker vaccine.
How can you check a shingles vaccine price and your bill in Korea?
Check HIRA's price, your local subsidy and the clinic's two-dose total before booking, then check the itemized bill after paying.
Before booking
- Search HIRA's non-covered fee information on hira.or.kr or in the Health e-Eum (Geongang e-Eum) app. Type Shingrix or SkyZoster and filter by province and institution type.
- Compare the clinic with the area median. The comparison screens show regional medians and medians by institution size, and they link to KDCA's vaccination helper site (Yebangjeopjong Doumi).
- Call your public health center (bogeonso). Ask about eligible ages, income limits, required length of residence, past vaccination, and whether support covers one dose or two.
- Confirm the total with the clinic: the price of both Shingrix doses, the date of the second dose, any separate fees, and whether you will be billed the posted price.
After paying
- Compare the receipt with the posted price. Institutions report to HIRA at set times, so treat HIRA's figure as a reference and check the clinic's own price list on the day of your visit.
- Ask for the detailed statement of charges (jillyobi sebu sanjeong naeyeokseo). It lists each item and shows whether it was billed as covered or non-covered.
- File a medical fee confirmation request (jillyobi hwagin yocheong) on hira.or.kr or in Health e-Eum if an item billed as non-covered looks like it should have been covered. Attach the receipt and the statement, and HIRA reviews the charges and refunds any overcharge. The vaccine itself is genuinely non-covered, so take a charge above its posted price to the clinic first and then to the public health center.
What do patients ask most about shingles vaccine cost in Korea?
What does non-covered mean for a shingles vaccine?
The vaccine sits outside National Health Insurance, so you pay the full price and each institution sets it. That is why shingles vaccine cost in Korea varies by clinic around a 2024 Shingrix median of 250,000 won per dose.Why do some reports quote 400,000 won or more?
Those are maximum prices, not typical ones. HIRA's 2025 data put the Shingrix maximum at 420,000 won and the Zostavax maximum at 400,000 won, against a 2024 Shingrix median of 250,000 won.Why can a tertiary hospital be cheaper than a local clinic?
Vaccine prices do not rise with hospital size. In 2024 the Shingrix mean was 240,000 won at tertiary hospitals and 250,000 won at clinics. For SkyZoster the figures were 139,000 won and 145,000 won.Will the shingles vaccine be free or covered by insurance in 2027?
No decision makes it free in 2027. In October 2026 KDCA said adding the vaccine to the NIP could be discussed, starting with high-risk groups, with health insurance coverage among the funding options. No start date, age group or product has been set, and 23.9% of local governments offer no support in 2026.Do foreign patients pay the same price?
Yes. HIRA discloses prices by institution and service, not by nationality, so the clinic's posted price applies: about 500,000 won for two Shingrix doses at the 2024 median. Each local government sets its own subsidy rules, so registered foreign residents should ask their public health center whether they qualify.What should patients check now, and what should they watch next?
Product choice and local subsidy move the shingles vaccine bill far more than hospital type does. In 2024 Shingrix centered on 250,000 won per dose, and a full course cost about 3.4 times one SkyZoster shot.
Before the visit, match the product to the patient's immune status and compare the clinic with the area median in HIRA's lookup. Ask the public health center about subsidies, and get the two-dose total from the clinic in advance. Afterward, check the receipt against the posted price and keep the detailed statement of charges.
Three developments would change that advice:
- KDCA's choice of target group, product and funding route under the new Vaccination Management Act. A high-risk-only start would leave healthy adults over 50 paying the clinic price.
- The next annual HIRA disclosure, which will show whether Shingrix holds at 250,000 won per dose.
- Local subsidy rules, which decide whether a patient pays all, part or none of the price.
What else should you read on Korea's non-covered prices?
- Dental Implant Cost Korea 2026: Prices and 2027 Senior Coverage: how a coverage rule for older adults changes what patients pay for a self-paid item.
- Brain MRI Cost in Korea 2026: HIRA Prices and the Headache Rule: an item where hospital type does drive the price.
- Shockwave Therapy Cost in Korea 2026 After Manual Therapy Reform: how to read clinic-level price distributions and dispute a bill.